Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 3Terminated 2Unknown 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Other 1NET 1CNS 1

Conditions

Breast Neoplasms 413Carcinoma, Non-Small-Cell Lung 286Prostatic Neoplasms 208Neoplasms 204Neoplasm Metastasis 180Melanoma 164Multiple Myeloma 158Colorectal Neoplasms 158Leukemia, Myeloid, Acute 143Lung Neoplasms 132Leukemia 126Lymphoma 118Pancreatic Neoplasms 117Recurrence 111Ovarian Neoplasms 111Leukemia, Lymphocytic, Chronic, B-Cell 110Lymphoma, Non-Hodgkin 105Carcinoma, Renal Cell 104Brain Neoplasms 90Myelodysplastic Syndromes 88Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Glioblastoma 85Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Follicular 79Carcinoma, Hepatocellular 79Head and Neck Neoplasms 77Squamous Cell Carcinoma of Head and Neck 76Urinary Bladder Neoplasms 66Stomach Neoplasms 61Hodgkin Disease 60

Interventions

pertuzumab 1Observation 1Erlotinib Hydrochloride 1Adrenalectomy 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Adrenal Gland Neoplasms × Clear all
NCT02001051 2018-06-14

Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 10 charts
EndocrineOther

Adrenal incidentaloma, Adrenal Gland Neoplasms, Cushing Syndrome, Diabetes Mellitus, Hypercholesterolemia, Hypertension, Obesity, Osteoporosis

NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡